NUS PEMF Magnetic Pulses Reprogram Immune Cells Against Breast Cancer
Analysis based on 10 articles · First reported Sep 13, 2026 · Last updated Sep 15, 2026
This breakthrough could positively impact the biotechnology and pharmaceutical sectors by offering a non-invasive, drug-free alternative for breast cancer treatment, potentially reducing reliance on chemotherapy and its side effects. However, commercial impact remains years away pending Phase 2 trials and regulatory approvals from agencies such as the Singapore Singapore — Health Sciences Authority and the US United States — Food and Drug Administration.
Researchers at the National University of Singapore (NUS) have demonstrated a non-invasive approach for targeted breast cancer therapy using pulsed electromagnetic fields (PEMFs). The study, led by Associate Professor Alfredo Franco-Obregon from the NUS Yong Loo Lin School of Medicine and the NUS Institute for Health Innovation & Technology, was published in the journal Smart Medicine on 4 June 2026. The team successfully reprogrammed tumour-associated macrophages (TAMs), immune cells that typically promote cancer growth, into an active anti-tumour state that attacks and destroys cancer cells. In preclinical models, PEMF treatment completely eradicated tumours in 75 per cent of tested models after just four 30-minute sessions, without chemotherapy. The key mechanism involves the TRPC1 protein, which acts as a molecular switch; a brief 10-minute PEMF exposure activated TRPC1 channels on M2-like TAMs, converting them to the M1 state. The same PEMF device has completed Phase 1 clinical trials demonstrating safety in humans, and the team is now seeking partners for Phase 2 efficacy trials. The research builds on earlier work showing that PEMF exposure enhances uptake of the chemotherapy drug doxorubicin by breast cancer cells, potentially halving the effective dosage needed. The team is optimistic the therapy could be a complementary treatment for other cancers beyond breast cancer. Breast cancer cases are projected to rise by a third, from 2.3 million in 2023 to more than 3.5 million by 2050, underscoring the urgent need for innovative therapies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard